Co-Authors
This is a "connection" page, showing publications co-authored by Laura Baker and Suzanne Craft.
Connection Strength
4.979
-
Craft S, Cholerton B, Baker LD. Insulin and Alzheimer's disease: untangling the web. J Alzheimers Dis. 2013; 33 Suppl 1:S263-75.
Score: 0.439
-
Baker LD, Bayer-Carter JL, Skinner J, Montine TJ, Cholerton BA, Callaghan M, Leverenz JB, Walter BK, Tsai E, Postupna N, Lampe J, Craft S. High-intensity physical activity modulates diet effects on cerebrospinal amyloid-ß levels in normal aging and mild cognitive impairment. J Alzheimers Dis. 2012; 28(1):137-46.
Score: 0.410
-
Baker LD, Asthana S, Cholerton BA, Wilkinson CW, Plymate SR, Green PS, Merriam GR, Fishel MA, Watson GS, Cherrier MM, Kletke ML, Mehta PD, Craft S. Cognitive response to estradiol in postmenopausal women is modified by high cortisol. Neurobiol Aging. 2012 Apr; 33(4):829.e9-20.
Score: 0.399
-
Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol. 2011 Jan; 68(1):51-7.
Score: 0.374
-
Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTiernan A, Cholerton BA, Plymate SR, Fishel MA, Watson GS, Duncan GE, Mehta PD, Craft S. Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer's disease. J Alzheimers Dis. 2010; 22(2):569-79.
Score: 0.357
-
Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTiernan A, Plymate SR, Fishel MA, Watson GS, Cholerton BA, Duncan GE, Mehta PD, Craft S. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol. 2010 Jan; 67(1):71-9.
Score: 0.357
-
Craft S, Claxton A, Baker LD, Hanson AJ, Cholerton B, Trittschuh EH, Dahl D, Caulder E, Neth B, Montine TJ, Jung Y, Maldjian J, Whitlow C, Friedman S. Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial. J Alzheimers Dis. 2017; 57(4):1325-1334.
Score: 0.145
-
Cholerton B, Baker LD, Montine TJ, Craft S. Type 2 Diabetes, Cognition, and Dementia in Older Adults: Toward a Precision Health Approach. Diabetes Spectr. 2016 Nov; 29(4):210-219.
Score: 0.143
-
Skinner JS, Morgan A, Hernandez-Saucedo H, Hansen A, Corbett S, Arbuckle M, Leverenz JB, Wilkins CH, Craft S, Baker LD. Associations between Markers of Glucose and Insulin Function and Cognitive Function in Healthy African American Elders. J Gerontol Geriatr Res. 2015 Aug; 4(4).
Score: 0.131
-
Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, Callaghan M, Arbuckle M, Behl C, Craft S. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. J Alzheimers Dis. 2015; 44(3):897-906.
Score: 0.126
-
Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, Callaghan M, Arbuckle M, Behl C, Craft S. Long Acting Intranasal Insulin Detemir Improves Cognition for Adults with Mild Cognitive Impairment or Early-Stage Alzheimer's Disease Dementia. J Alzheimers Dis. 2015; 45(4):1269-70.
Score: 0.126
-
Hanson AJ, Bayer JL, Baker LD, Cholerton B, VanFossen B, Trittschuh E, Rissman RA, Donohue MC, Moghadam SH, Plymate SR, Craft S. Differential Effects of Meal Challenges on Cognition, Metabolism, and Biomarkers for Apolipoprotein E ?4 Carriers and Adults with Mild Cognitive Impairment. J Alzheimers Dis. 2015; 48(1):205-18.
Score: 0.126
-
Cholerton B, Baker LD, Craft S. Insulin, cognition, and dementia. Eur J Pharmacol. 2013 Nov 05; 719(1-3):170-179.
Score: 0.115
-
Hanson AJ, Bayer-Carter JL, Green PS, Montine TJ, Wilkinson CW, Baker LD, Watson GS, Bonner LM, Callaghan M, Leverenz JB, Tsai E, Postupna N, Zhang J, Lampe J, Craft S. Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. JAMA Neurol. 2013 Aug; 70(8):972-80.
Score: 0.114
-
Claxton A, Baker LD, Wilkinson CW, Trittschuh EH, Chapman D, Watson GS, Cholerton B, Plymate SR, Arbuckle M, Craft S. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease. J Alzheimers Dis. 2013; 35(4):789-97.
Score: 0.110
-
Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012 Nov; 69(11):1420-9.
Score: 0.108
-
Cholerton B, Baker LD, Trittschuh EH, Crane PK, Larson EB, Arbuckle M, Saucedo HH, McCurry SM, Bowen JD, McCormick WC, Craft S. Insulin and sex interactions in older adults with mild cognitive impairment. J Alzheimers Dis. 2012; 31(2):401-10.
Score: 0.102
-
Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012 Jan; 69(1):29-38.
Score: 0.100
-
Bayer-Carter JL, Green PS, Montine TJ, VanFossen B, Baker LD, Watson GS, Bonner LM, Callaghan M, Leverenz JB, Walter BK, Tsai E, Plymate SR, Postupna N, Wilkinson CW, Zhang J, Lampe J, Kahn SE, Craft S. Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment. Arch Neurol. 2011 Jun; 68(6):743-52.
Score: 0.098
-
Trittschuh EH, Crane PK, Larson EB, Cholerton B, McCormick WC, McCurry SM, Bowen JD, Baker LD, Craft S. Effects of varying diagnostic criteria on prevalence of mild cognitive impairment in a community based sample. J Alzheimers Dis. 2011; 25(1):163-73.
Score: 0.096
-
VanFossen BT, Watson GS, Baker LD, Rhoads KW, Cholerton BA, Reger MA, Plymate SR, Schellenberg G, Craft S. Statin users without an APOE-epsilon4 allele have increased insulin resistance. J Alzheimers Dis. 2010; 19(4):1149-53.
Score: 0.089
-
Watson GS, Baker LD, Cholerton BA, Rhoads KW, Merriam GR, Schellenberg GD, Asthana S, Cherrier M, Craft S. Effects of insulin and octreotide on memory and growth hormone in Alzheimer's disease. J Alzheimers Dis. 2009; 18(3):595-602.
Score: 0.083
-
Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey WH, Craft S. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis. 2008 Apr; 13(3):323-31.
Score: 0.079
-
Watson GS, Bernhardt T, Reger MA, Cholerton BA, Baker LD, Peskind ER, Asthana S, Plymate SR, Frölich L, Craft S. Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease. Neurobiol Aging. 2006 Jan; 27(1):38-41.
Score: 0.068
-
Watson GS, Reger MA, Baker LD, McNeely MJ, Fujimoto WY, Kahn SE, Boyko EJ, Leonetti DL, Craft S. Effects of exercise and nutrition on memory in Japanese Americans with impaired glucose tolerance. Diabetes Care. 2006 Jan; 29(1):135-6.
Score: 0.068
-
Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry. 2005 Nov; 13(11):950-8.
Score: 0.067
-
Fishel MA, Watson GS, Montine TJ, Wang Q, Green PS, Kulstad JJ, Cook DG, Peskind ER, Baker LD, Goldgaber D, Nie W, Asthana S, Plymate SR, Schwartz MW, Craft S. Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol. 2005 Oct; 62(10):1539-44.
Score: 0.066
-
Reger MA, Henderson ST, Hale C, Cholerton B, Baker LD, Watson GS, Hyde K, Chapman D, Craft S. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging. 2004 Mar; 25(3):311-4.
Score: 0.059
-
Reger MA, Welsh RK, Watson GS, Cholerton B, Baker LD, Craft S. The relationship between neuropsychological functioning and driving ability in dementia: a meta-analysis. Neuropsychology. 2004 Jan; 18(1):85-93.
Score: 0.059
-
Craft S, Asthana S, Cook DG, Baker LD, Cherrier M, Purganan K, Wait C, Petrova A, Latendresse S, Watson GS, Newcomer JW, Schellenberg GD, Krohn AJ. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology. 2003 Aug; 28(6):809-22.
Score: 0.057
-
Baker LD, Sambamurti K, Craft S, Cherrier M, Raskind MA, Stanczyk FZ, Plymate SR, Asthana S. 17beta-estradiol reduces plasma Abeta40 for HRT-naïve postmenopausal women with Alzheimer disease: a preliminary study. Am J Geriatr Psychiatry. 2003 Mar-Apr; 11(2):239-44.
Score: 0.055
-
Robertson K, Larson EB, Crane PK, Cholerton B, Craft S, McCormick WC, McCurry SM, Bowen JD, Baker LD, Trittschuh EH. Using Varying Diagnostic Criteria to Examine Mild Cognitive Impairment Prevalence and Predict Dementia Incidence in a Community-Based Sample. J Alzheimers Dis. 2019; 68(4):1439-1451.
Score: 0.042
-
Gifford AR, Lawrence JA, Baker LD, Balcueva EP, Case D, Craft S, Curtis AE, Griffin L, Groteluschen DL, Klepin HD, Lesser GJ, Messino MJ, Naughton M, Samuel TA, Rapp S, Sachs B, Sink KM, Williamson J, Shaw EG. National Institute on Aging /Alzheimer's Association criteria for Mild Cognitive Impairment applied to chemotherapy treated breast cancer survivors. J Oncol Research. 2017; 1(1).
Score: 0.038
-
Hughes TM, Craft S, Baker LD, Espeland MA, Rapp SR, Sink KM, Bertoni AG, Burke GL, Gottesman RF, Michos ED, Luchsinger JA, Fitzpatrick AL, Hayden KM. Changes in metabolic risk factors over 10 years and their associations with late-life cognitive performance: The Multi-Ethnic Study of Atherosclerosis. Alzheimers Dement (Amst). 2017; 8:18-25.
Score: 0.037
-
Willette AA, Johnson SC, Birdsill AC, Sager MA, Christian B, Baker LD, Craft S, Oh J, Statz E, Hermann BP, Jonaitis EM, Koscik RL, La Rue A, Asthana S, Bendlin BB. Insulin resistance predicts brain amyloid deposition in late middle-aged adults. Alzheimers Dement. 2015 May; 11(5):504-510.e1.
Score: 0.031
-
Friedman SD, Baker LD, Borson S, Jensen JE, Barsness SM, Craft S, Merriam GR, Otto RK, Novotny EJ, Vitiello MV. Growth hormone-releasing hormone effects on brain ?-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurol. 2013 Jul; 70(7):883-90.
Score: 0.028
-
Cholerton B, Larson EB, Baker LD, Craft S, Crane PK, Millard SP, Sonnen JA, Montine TJ. Neuropathologic correlates of cognition in a population-based sample. J Alzheimers Dis. 2013; 36(4):699-709.
Score: 0.027
-
Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, Ismail MS, Martin BK, Mullan MJ, Sabbagh M, Tariot PN. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement. 2011 Jul; 7(4):402-11.
Score: 0.025
-
Wharton W, Baker LD, Gleason CE, Dowling M, Barnet JH, Johnson S, Carlsson C, Craft S, Asthana S. Short-term hormone therapy with transdermal estradiol improves cognition for postmenopausal women with Alzheimer's disease: results of a randomized controlled trial. J Alzheimers Dis. 2011; 26(3):495-505.
Score: 0.024